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Abstract. Human telomerase reverse transcriptase (hTERT) 
expression level may not always correlate with telomerase 
activity. The present study analyzed hTERT splicing patterns 
with respect to hTERT and telomerase activity in colorectal 
cancer. Telomerase activity was determined by telomeric 
repeat amplification protocol assay, and spliced variants of 
hTERT were identified by reverse transcription‑polymerase 
chain reaction in 40 colorectal cancer tissue samples. In the 
lower range of telomerase activity (0‑100 units), the percentage 
of the β variant decreased with the increment in telomerase 
activity, whereas in the higher range of telomerase activity 
(>100 units), total hTERT expression level revealed a trend 
toward increment. There was a positive correlation between 
the full‑length variant level and β variant level. Conversely, 
there was a negative correlation between the percentage of the 
full‑length variant and β variant. Tumor-node-metastasis stage 
was the strongest prognostic factor in multivariate analysis 
and the percentage of the full‑length variant was an indepen-
dent prognostic factor for survival. Telomerase activity was 
primarily altered with changes in alternative splicing of the 
full‑length and β variants of hTERT in colorectal cancer.
Introduction
Functional human telomerase reverse transcriptase (hTERT) 
mRNA is detected in lymphocytes (1) and in the normal brain, 
liver, prostate, heart and primary fibroblasts, irrespective of 
the degree of telomerase activity (2). The full‑length Yonsei 
hTERT variant is associated with high telomerase activity (3). 
However, the presence of a full‑length hTERT variant is not 
sufficient to allow telomerase activity when an abundance of 
multiple hTERT spliced variants is concomitantly present (4).
A total of 6 alternative splicing sites (4 insertion and 2 dele-
tion) have been identified within hTERT mRNA (5). Splice 
variants, depending on tissue type, continued to be synthesized 
even when the full‑length variant was not (6). The presence 
of alternatively spliced variants in human preimplantation 
embryos may suggest a lack of telomerase activity, resulting 
in the appearance of chromosomes with shortened telo-
meres (7,8). The exact functions of each alternatively spliced 
variant of hTERT remain unknown, although the positions 
of the spliced sites suggest that the majority of the variants 
do not code for functional reverse transcriptase. Depending 
on the cell line, this telomerase inhibition resulted either in 
cell death or a senescence-like state (9). The β splice variant 
did not reconstitute active telomerase activity in a previous 
in vitro transcription and translation study (10). The alteration 
of hTERT full‑length variant expression levels has previously 
been reported to demonstrate various gene expression profiles 
and genomic copy number changes in cancer cell lines (11).
In telomerase-positive cell lines, there is a highly 
uniform pattern of splicing. In total, ~5% of hTERT mRNA 
is in full‑length form, 80‑90% in β‑spliced form, 5‑15% in 
α/β‑spliced form and <1% in α‑spliced form (12). However, 
in contrast, considerable variation in the total number and 
quantitative distribution of spliced variants has been observed 
in various cancer tissues and in normal tissues. In renal 
cell carcinoma, the β variant was the major type and the α 
variant was not detected (13). In breast cancer, the α variant 
was always coexpressed with the full‑length and/or β variant, 
otherwise, the full‑length and β variant were observed either 
in combination with other transcripts or expressed as the 
only hTERT transcript (14). Melanoma expressed full‑length 
transcripts with various combinations of α, β and α/β variants, 
although a prevalence of the β variant was observed (4).
The presence of a full‑length variant was correlated with 
telomerase activity in the endometrium and myometrium (15). 
Two potential mechanisms underlying the reduction of 
telomerase activity with differentiation have previously been 
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suggested: One is the post-translational alterations in hTERT 
with stable total transcription and splicing patterns, and the 
other is the minimal change in total transcription with a 
dramatic decrease of the full‑length variant, predominantly 
remaining in β‑spliced form (13).
The aim of the present study was to analyze the hTERT 
splicing pattern in association with telomerase activity in 
patients with colorectal cancer.
Materials and methods
Tissue sampling and RNA isolation. A total of 40 patients who 
underwent surgery between May 2002 and May 2003 at Yonsei 
Cancer Center, Severance Hospital, Yonsei University Health 
System (Seoul, Korea) were enrolled in the present study. 
Clinical characteristics of the patients are listed in Table I. 
Paired tumor tissues and normal tissues from 30 patients and 
tumor tissues alone from 10 patients were studied. Tumor 
tissues (≥70% carcinoma cellularity) were frozen immediately 
following surgery. In paired samples, normal tissues 10 cm 
from the lateral margin of the primary tumor were obtained. 
Total RNA was isolated from cells and tissues using TRIzol 
reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA), according to the manufacturer's protocol. 
Approval for the present study was obtained from the institu-
tional review board of the Severance Hospital (Seoul, Korea; 
approval no. IRB‑4‑2004‑0083). Written, informed consent 
was obtained from all patients for the use of the samples in 
the present study.
Telomeric repeat amplification protocol (TRAP) assay. Each 
tissue sample was washed in ice‑cold wash buffer [10 mM 
Hepes-KOH (pH 7.5), 1.5 mM MgCl2, 10 mM KCl, 1 mM 
dithiothreitol] and then homogenized with 100 µl ice-cold 
lysis buffer [10 mM Tris‑HCl (pH 7.5), 1 mM MgCl2, 1 mM 
egtazic acid (EGTA), 0.1 mM phenylmethylsulfonyl fluoride, 
5 mM β‑mercaptoethanol, 0.5% CHAPS, 10% glycerol]. The 
TRAP assay was performed as follows: A total of 20 µl of each 
extract was assayed in a 50 µl reaction mixture supplemented 
with 20 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 63 mM KCl, 
0.005% Tween‑20, 1 mM EGTA, 50 µM deoxynucleotide 
triphosphates, 0.5 µl (α-32P) deoxycytidine triphosphate (dCTP; 
3,000 Ci/mmol; GE Healthcare Life Sciences, Chalfont, UK), 
0.1 µg template‑switching oligonucleotide (5'‑AAT CCG TCG 
AGC AGA GTT‑3'), 1 µg T4 gene 32 protein, bovine serum 
albumin (0.1 mg/ml; Sigma‑Aldrich; Merck KGaA, Darmstadt, 
Germany) and 2 U Taq DNA polymerase (Applied Biosystems; 
Thermo Fisher Scientific, Inc.) in an assay tube supplemented 
with 0.1 µg CX primer (5'‑CCC TTA CCC TTA CCC TTA CCC 
TAA‑3'). The reaction mixture was amplified for 30 cycles at 
94˚C for 30 sec, 50˚C for 30 sec, 72˚C for 90 sec, and then for 
10 min at 72˚C. Analysis of 10 µl of each polymerase chain 
reaction (PCR) product was performed on 12% non‑denaturing 
acrylamide gels. The present study also determined the optical 
density (OD) of the bands in the film by computer‑assisted 
densitometry (Vilber Lourmat Vision‑Capt software version 
1; Vilber Lourmat, Marne‑la‑Vallée, France). The OD of the 
band with the greatest density in 6 µg protein from the human 
normal kidney immortalized cell line which displays telom-
erase activity (HEK‑293 cell line) was arbitrarily defined as 
100 U (16). In order to compare the ODs of telomerase activity 
from each tissue with the same baseline, TRAP assays were 
performed using the same amount of tissue extracts (6 µg) in 
all 40 patients. The bands from each tissue were compared 
with the control (HEK-293 cell line) and expressed in arbitrary 
units (11,17,18).
Alternative splicing of hTERT. Total RNA was collected from 
samples using TRIzol‑Reagent (Thermo Fisher Scientific, Inc.). 
First‑strand cDNA synthesis was performed according to the 
manufacturer's protocol. Total RNA (1 µg), oligo(dT) primer, 
10 mM dNTPs and M‑MuLV reverse transcriptase (Fermentas; 
Thermo Fisher Scientific, Inc.) was used to synthesize cDNA 
for each sample. In order to evaluate hTERT mRNA splicing, 
the present study performed reverse transcription‑PCR using 
primer sets for the reverse transcriptase domain of the hTERT 
transcript (19). The cDNA samples were amplified in a 5 µl 
reaction mixture supplemented with 0.25 uCi (α-32P) dCTP 
(GE Healthcare Life Sciences) and 0.2 µM of each primer. 
The first hTERT cDNA amplification used TERT‑1784S, 
5'‑CGG AAG AGT GTC TGG AGC AA‑3' and TERT‑1928A, 
5'‑GGA TGA AGC GGA GTC TGG A‑3' oligonucleotides with 
an initial heating at 94˚C for 90 sec, followed by 33 cycles of 
95˚C for 20 sec, 68˚C for 40 sec and 72˚C for 30 sec. Primers 
774 (forward; 5'‑GGG AAT TCA AAA CTG GAA CGG TGA 
AGG‑3') and 775 (reverse; 5'‑GGA AGC TTA TCA AAG TCC 
TCG GCC ACA‑3') were added at 72˚C during cycle 13 as a 
β‑actin internal control. The second hTERT cDNA amplifi-
cation used TERT‑2164S sense, 5'‑GCC TGA GCT GTA CTT 
TGT CAA‑3' and TERT‑2620A anti‑sense, 5'‑CGC AAA CAG 
CTT GTT CTC CAT GTC‑3' oligonucleotides (6) with an initial 
heating at 94˚C for 90 sec, followed by 35 cycles of 95˚C for 
25 sec, 68˚C for 50 sec and 72˚C for 50 sec. Primers 774 and 
775 were added at 72˚C during cycle 15 as a β-actin internal 
control. Bands from each tissue were compared with the 
control and expressed in arbitrary units. The HL‑60 cell line 
(American Tissue Type Culture Collection, Manassas, VA, 
USA) was used as a positive control for the expression level of 
alternatively spliced variants.
Statistical analysis. Clinical data were retrieved from the 
medical records of Severance Hospital (Seoul, Korea). The χ2 
test or Mann‑Whitney U tests were used for categorical vari-
ables and the Student's t‑test was used to compare continuous 
variables. Progression‑free survival (PFS) was defined as the 
time interval between the date of surgery and disease progres-
sion or mortality from any cause. Overall survival (OS) was 
evaluated from the date of surgery to mortality or last contact 
(censored observation). Survival curves were estimated 
using the Kaplan‑Meier method and differences in survival 
curves among groups were compared using the log-rank test. 
Univariate associations between prognostic factors and OS 
and between prognostic factors and PFS were assessed using 
the log‑rank test. In order to adjust for confounding variables, 
Cox proportional hazards models were used to estimate the 
simultaneous effects of prognostic factors on survival. All tests 
were two‑sided and P<0.05 was considered to indicate a statis-
tically significant difference. All analyses were performed 
using SPSS for Windows (version 13.0; SPSS, Inc., Chicago, 
IL, USA).
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Results
Patient characteristics. Of the 40 patients enrolled in the 
present study, the median follow‑up duration was 69.5 months 
(range, 7.4‑76.3 months). During the follow‑up period, 12 
(30.0%) of patients relapsed and 9 (22.5%) succumbed to 
colorectal cancer. The five‑year DFS and OS rates were 
76.3% and 81.6%, respectively. Other clinical characteristics 
are summarized in Table I.
Expression levels of telomerase activity and hTERT. Of the 
40 tumor tissues, 32 (80%) expressed telomerase activity and 
32 (80%) expressed hTERT. Of the 32 patients with telom-
erase activity, 26 (81%) expressed hTERT. In the 8 patients 
without telomerase activity, 6 (75%) expressed hTERT. A 
total of 2 patients did not express telomerase activity or 
hTERT (Table II).
In the lower range of telomerase activity (0‑100 U), 
the percentage of β variant decreased with the increment 
in telomerase activity (P=0.048), whereas hTERT did not 
significantly differ. In the higher range of telomerase activity 
(≥100 U), total hTERT level revealed a trend toward incre-
ment (P=0.06) without any difference in the percentage of 
each spliced type (Table III; Fig. 1). These results suggested 
that a change of β variant percentage was the main mecha-
nism during the early phase and that hTERT increment was 
the main mechanism of the late phase of telomerase activity 
increment in colorectal cancer.
Expression levels of hTERT splicing variants. Among the 
30 paired normal tissues, 1 patient (3.3%) expressed a low 
level of telomerase activity (36 U) and 1 patient expressed 
hTERT (20 U). A total of 4 patients (13.3%) expressed alter-
natively spliced variants [1 full‑length (87 U), α (25 U), β 
(120 U) variants; 1 full‑length (1 U) and β (1 U) variants; 2 
β variant alone (12, 21 U)]. In cancer tissues with telomerase 
activity, 17 (53%) of patients expressed all 4 types of vari-
ants (full length, α, β and α/β). A total of 7 patients (22%) 
expressed full‑length, β and α/β variants. A total of 3 (9%) 
patients expressed full length and β variants (Fig. 2). A total 
of 3 patients expressed none of the hTERT types, even with 
telomerase activity expression. Of the 8 patients without 
telomerase activity, 2 did not express any hTERT splicing 
type. A total of 2 patients expressed all 4 types (Table IV).
Table I. Patient characteristics.
Clinical factors  Patient number (%)
Age (median, range; years) 66 (44‑81)
Sex 
  Male 25 (62.5)
  Female 15 (37.5)
Eastern Cooperative Oncology Groupa 
  0-1 40 (100)
Primary site 
  Colon cancer 23 (57.5)
  Rectal cancer 17 (42.5)
Stage (Duke)b 
  A 1 (2.5)
  B 21 (52.5)
  C 13 (32.5)
  D 5 (12.5)
Stage (TNM) 
  I 3 (7.5)
  II 19 (47.5)
  III 13 (32.5)
  IV 5 (12.5)
Operation type 
  Low anterior resection 26 (65.0)
  Right hemicolectomy 9 (22.5)
  Left hemicolectomy 5 (12.5)
Relapse 
  No recurrence 28 (70.0)
  Recurrence 12 (30.0)
Survival rate 
  Survived 31 (77.5)
  Succumbed 9 (22.5)
Follow-up duration 69.5 (7.4‑76.3)
(median, range; months)
aOken et al (31). bAstler and Coller (32). TNM, tumor-node-metastasis.
Table III. Comparison of telomerase activity and percent frac-
tion of hTERT variants.
Telomerase
activity range and Full    hTERT
mean ± SD (U)  (%) α (%) β (%) αβ (%) (U)
0-50 (8±11) 22±13 2±2 71±18a 5±4 63±47b
51-100 (75±14) 34±21 4±4 53±23a 9±7 51±79
101-200 (122±21) 31±6 3±3 58±7 10±8 58±36
>200 (323±76) 25±15 4±3 65±19 6±5 101±55b
hTERT, human telomerase reverse transcriptase; SD, standard devia-
tion; α, α variant; β, β variant; αβ, α/β variant. aβ (%) in telomerase 
activity 0‑50 group vs. 51‑100 group, P=0.048; bhTERT (U) in telom-
erase activity 0‑50 group vs. >200 group, P=0.06.
Table II. Comparison of telomerase activity and hTERT 
expression levels in colon cancer tissues (n=40).
Telomerase activity hTERT expression Patient no. (%)
Positive Expressed 26 (65%)
Positive Non‑expressed 6 (15%)
Negative Expressed 6 (15%)
Negative Non‑expressed 2 (5%)
hTERT, human telomerase reverse transcriptase.
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Comparison of telomerase activity based on hTERT splicing 
variant expression level. There was no difference in telom-
erase activity in each group when telomerase activity based on 
the expression levels of splicing types was compared; however, 
hTERT expression levels were lower in 2 groups (full‑length, β 
and α/β; P=0.09; and full‑length, β; P<0.0008) compared with 
the group with all 4 variant types expressed (Table IV).
There was no correlation between telomerase activity and 
expression level of each variant. However, among the variants, 
there was a positive correlation between full‑length variant 
level and β variant level (r=0.88, P<0.001; Fig. 3). Conversely, 
there was a negative correlation in the percentage between 
the full‑length variant and β variant (r=‑0.939, P<0.001; 
Fig. 3). Expression fractions of full‑length and β variants were 
Figure 2. A total of 8 paired normal and cancer tissues that expressed full‑length, α, β or αβ variants and hTERT compared with actin expression levels. hTERT, 
human telomerase reverse transcriptase; bp, base pair; N, normal tissue; T, tumor tissue.
Figure 1. Changes in hTERT expression levels, percent fractions of full‑length and β variants based on the alterations in telomerase activity. (A) Changes in 
telomerase activity. (B) Changes in hTERT expression level, including full‑length and β variants. hTERT, human telomerase reverse transcriptase. *P=0.048, 
β (%) in telomerase activity 0‑50 group vs. 51‑100 group and **P=0.06, hTERT (U) in telomerase activity 0‑50 group vs. >200 group.
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Table IV. Expression level of hTERT splicing variants based on telomerase activity.
Group Patient number Telomerase activity (U) hTERT expression level (U)
Telomerase activity (+) (n=32)
  Full/α/β/αβ 17 146±130 92±62a,b
  Full/β/αβ 7 111±133 55±45a
  Full/β 3 144±149 13±14b
  Full/α/β 1 95 1
  β 1 21 0
  None  3 210±336 0
Telomerase activity (-) (n=8)
  Full/α/β/αβ 2  
  Full/α/αβ 2  
  β/αβ 1  
  β 1  
  None 2  
ahTERT expression level in Full/α/β/αβ group vs. Full/β/αβ group, P=0.09; bhTERT expression level in Full/α/β/αβ group vs. Full/β group, 
P<0.0008. hTERT, human telomerase reverse transcriptase; α, α variant; β, β variant; αβ, α/β variant.
Figure 3. Correlations of hTERT, full‑length and β variant expression levels. (A) Positive correlation of expression levels of full‑length and β variants. 
(B) Negative correlation of percent fractions between full‑length and β variants. (C) Positive correlation of expression levels between full‑length variants and 
hTERT. (D) Positive correlation of expression levels between β variant and hTERT. hTERT, human telomerase reverse transcriptase.
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positively correlated with hTERT expression level (r=0.71, 
P<0.001 and r=0.66, P<0.001, respectively; Fig. 3). Even if 
total levels of full length and β variants increased with the 
increment of hTERT expression level, the main factor for the 
hTERT increment was full‑length variant increment, which 
resulted in a negative correlation between hTERT level and 
percent fraction of β variant. This finding suggested that 
full‑length variant was the main subtype of splicing during the 
increment of hTERT in colorectal cancer.
Comparison of clinical parameters with splicing type 
pattern. The present study compared the hazard ratio for 
survival with clinical factors [age, sex, tumor‑node‑metas-
tasis (TNM) stage (20)] and molecular markers (telomerase 
activity, percent fraction of alternative splicing types, 
hTERT). TNM stage was demonstrated to be the strongest 
prognostic factor by multivariate analysis, and percent frac-
tion of the full‑length variant was an independent prognostic 
factor for survival (Table V).
Discussion
The discrepancy between telomerase activity and the hTERT 
mRNA expression levels may be due to the difficulty of quan-
tification of either telomerase activity or hTERT expression 
level, constituents of intratumoral lymphocytes or leukocytes 
or the presence of heterogeneity in tumor tissues. Finally, 
post‑transcriptional modification of telomerase activity by 
alternative splicing may result in truncated and potentially 
dysfunctional protein products.
The association of telomerase activity with the presence of 
the full‑length variant was significant (3). However, the pres-
ence of a full‑length hTERT variant was not sufficient to allow 
telomerase activity when an abundance of hTERT‑spliced 
variants were concomitantly present (11). In melanoma, 
the β‑spliced form was a negative regulator of telomerase 
activity (21). In the present study, 4 (12.5%) of the 32 patients 
with telomerase activity lacked the full length variant, and of 
the 8 patients without detectable telomerase activity, 4 (50%) 
lacked the full‑length variant and 4 (50%) lacked the β variant. 
These cases suggested the presence of an additional regulatory 
mechanism, for example post‑translational modification by 
phosphorylation or truncation outside the reverse transcriptase 
motif of hTERT.
Various splice variants, depending on the tissue type, 
continue to be synthesized when the full‑length variant is 
not (22). Two potential mechanisms underlying the decrement 
of telomerase activity with differentiation have been previ-
ously suggested (22,23). These are posttranslational alterations 
in hTERT with stable total transcription and splicing patterns, 
and minimal change in total transcription with a decrement of 
the full‑length variant predominantly remaining in β-spliced 
form (12). In a previous in vitro transcription and translation 
study, the β-splice variant was revealed to not reconstitute an 
active telomerase enzyme (3). It is possible that protein prod-
ucts of α- or β‑spliced transcripts are negative inhibitors of the 
formation of active telomerase enzymes. In the patients inves-
tigated in the present study, when there was a low increment 
of telomerase activity, the initial decrement of the β variant 
fraction was demonstrated without any specific increment of 
hTERT. However, in patients with high telomerase activity, 
total hTERT level was increased with stable maintenance of 
each variant fraction. Various regulatory mechanisms may be 
involved based on different levels of telomerase activity in 
colorectal cancer, including shifting of β variant fractions and 
total increments of hTERT.
In general, the band density of the full‑length variant was 
equal to or higher than that of alternatively spliced variants. 
Transcriptional activation of hTERT is not necessarily the 
rate‑limiting step in the generation of functional telomerase. 
The present study observed decreased hTERT levels without 
any changes in telomerase activity in patients without the 
α-splice variant compared with patients with all 4 variants. 
Although the α variant did not completely abolish telomerase 
activity, the resultant reduction in activity was sufficient to 
reverse the immortal phenotype (9). Clones expressing the 
α variant underwent apoptosis and clones expressing the 
β variant or α/β variant revealed no sign of apoptosis and 
continued to proliferate (12).
The hTERT level was positively correlated with expres-
sion levels of the full‑length variant and the β variant in the 
patients included in the present study. With the increment of 
total hTERT, the full‑length variant and β variant expression 
levels increased with positive correlations. However, when the 
percent fraction of each variant and hTERT expression level 
were compared, the full‑length variant was positively corre-
lated and the β variant was negatively correlated. Therefore, 
in patients with hTERT increment, the increment rate of the 
full‑length variant was higher than the increment rate of the 
β variant. As a result, even if the total amount of the β variant 
was increased, the total fraction was relatively low compared 
with the fraction of the full‑length variant. These relative 
changes in the fraction and total amount of each spliced 
variant may be the regulatory mechanism underlying hTERT, 
and thus telomerase activity in colorectal cancer. Of the tran-
scriptional regulators of hTERT, nuclear factor of activated 
T cells (24), SET and MYND domain‑containing protein 3, a 
histone methyltransferase (25), Mutant-S homolog 2, heteroge-
neous nuclear ribonuclear protein (hnRNP) D, hnRNP K and 
grainyhead-like 2 (26) have been observed in cancer cells, and 
mad1 was identified in myelodysplastic syndrome (27), which 
Table V. Multivariate analysis of hazard ratio for overall 
survival in patients with colorectal cancer.
Variable P‑value Hazard ratio 95% CI
Age 0.231 0.757 0.480-1.194
Sex  0.525 5.471 0.029-1033.948
Telomerase activity 0.596 0.994 0.973‑1.016
α/β ratio (%) 0.215 1.209 0.895‑1.633
TNM stage 0.027a 24.125 1.429-407.290
Full length (%) 0.037b 1.294 1.016‑1.647
hTERT 0.903 0.998 0.968‑1.029
CI, confidence interval; TNM, tumor‑node‑metastasis; hTERT, 
human telomerase reverse transcriptase. aP<0.05, TNM stage I=II vs. 
III+IV, bP<0.05, full Length (%) ≤50% vs. >50%. 
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may be targets for anti‑telomerase or anti‑hTERT treatment in 
cancer.
The cyclopentenone prostaglandin 15-deoxy-delta 
12,14-prostaglandin J2 demonstrated anti-neoplastic activity 
by decreasing hTERT expression level and suppressing c-Myc 
mRNA expression levels (28). A low dose of chelidonine 
reduced telomerase activity via downregulation of hTERT 
expression, suggesting that hTERT may be a potential target 
molecule in cancer (29). In the patients enrolled in the 
present study, there was no significant difference in clinical 
outcome between patients with telomerase-positive and nega-
tive colorectal cancer. However, the percent fraction of the 
full‑length variant was a prognostic factor, as was American 
Joint Committee on Cancer (TNM) stage. When developing 
an anti‑telomerase drug treatment, 80% of patients with 
colorectal cancer may be a potential target population, using 
hTERT variant as a patient selection biomarker (30).
In conclusion, telomerase activity changes and alternative 
splicing of full‑length and β variants of hTERT in colorectal 
cancer were demonstrated. Clinical trials with an anti-telom-
erase compound using alternative splicing variants as patient 
selection biomarkers are warranted for the validation of the 
clinical significance of hTERT variants in colorectal cancer.
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